1. 1. Cook JR, Isaacson PG, Chott A, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). Lyon: IARC; 2017:259-262.
2. 2. Freedman AS. Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT). In: Lister A, ed. UpToDate; 2021.
3. 3. Freedman AS. Clinical presentation and diagnosis of primary gastrointestinal lymphomas. In: Lister A, ed. UpToDate; 2021.
4. 4. Ohno H, IsodaK. t(11;18)(q21;q21)-positive advanced-stage MALT lymphoma associated with monoclonal gammopathy: Resistance to rituximab or rituximab-containing chemotherapy. J Clin Exp Hematop2008;48:47-54.
5. 5. Asatiani E, Cohen P, Ozdemirli M, et al. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol2004;77:144-146.